CDK4 and cancer: Several strategies are therefore being investigated to improve the efficacy of these agents by combining them with other anti-cancer therapies, such as PD-1/PD-L1 immune checkpoint inhibitors, chemotherapeutic agents, or targeted therapies, such as the PARP inhibitor, olaparib, and CDK4/6 inhibitors [87].